BANGKOK — OLIC (Thailand) Limited, Southeast Asia’s largest pharmaceutical contract development and manufacturing organization (CDMO), is strategically expanding its business focus into the women’s healthcare market with the introduction of several high-quality pharmaceutical products, including an innovative natural estrogen in combined oral contraceptive.
The company, a subsidiary of Japan’s Fuji Pharma Co., Ltd., is leveraging its four decades of manufacturing expertise to transition from being primarily a contract manufacturer to becoming a key player in women’s healthcare across Thailand and ASEAN markets.
“Today, OLIC is ready to become a leader in women’s healthcare by providing high-quality pharmaceutical products,” said Yoshihiro Takada, Managing Director of OLIC Thailand on March 7, 2025. The company’s product portfolio now includes natural estrogen in combined oral contraceptive, endometriosis medication, post-operative pain management treatments, and hormone replacement therapy.
Industry analysts note that this market entry is well-timed. The global women’s healthcare market is projected to reach USD 66 billion by 2033, with gynecological disorders representing the largest segment. In Southeast Asia, the contraceptive market alone is valued at 6 billion baht (approximately USD 170 million), with Thailand accounting for 50% of this market.
Pannavich Chitmetheepong, Pharma Business Unit Director at OLIC, announced that the company’s innovative natural estrogen oral contraceptive is now available at healthcare facilities and leading pharmacies throughout Thailand. He highlighted that the product “exhibits selective actions and improved safety profile, providing a new option for women in Thailand.”
To support its market expansion, OLIC has launched the ‘Be with HER – Empowering Her Health Decisions’ campaign, which includes educational content and engagement activities in collaboration with healthcare partners. This initiative aims to promote women’s health awareness and access to accurate medical information.
OLIC maintains dual operations with manufacturing facilities in Bang Pa-in Industrial Estate, Ayutthaya Province, and corporate offices in Bangkok’s Mitrtown Office Tower.
The company’s strategic pivot comes amid increasing healthcare expenditures across Southeast Asia and growing consumer demand for specialized women’s health products and services.
____________
